Medosome Biotec, LLC

Bloomington, IN 47401

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.46MM
First Award Date 09/15/15
Most Recent Award Date 07/01/17

Key Personnel

Last Name Name Awards Contact
WAGNER RICHARD WAGNER 2
RIVKEES SCOTT A. RIVKEES 1
WANG GARY P WANG 2
KANG PETER B. KANG 1
SRIVASTAVA ARUN SRIVASTAVA 1
STACPOOLE PETER WALLACE STACPOOLE 2
CHENG SAM X CHENG 1

9 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 07/01/17 - 08/31/18

Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated. Treatment of PDCD remains a serious, unmet, challenge. There has never been a controlled trial of any intervention for PDCD; thus, there is no proven therapy for affe...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 04/01/17 - 03/31/18

Project Abstract Acute infectious diarrhea is a worldwide problem, especially among infants, young children and immune-compromised patients. Sadly, 1.3 million children die each year, not because of the infections causing diarrhea, but due to the associated dehydration. The pro-absorptive Oral Rehydration Solution (ORS) is the only recommended ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 04/01/17 - 03/31/18

Project Summary/Abstract The objective of this Phase I STTR application is to develop a next generation quantitative drug resistance assay that can accurately determine the abundance and linkage of HCV variants resistant to direct-antiviral agents (DAAs). Drug resistance to HCV is a major threat to achieving sustained virologic response (SVR) in...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 09/14/16 - 08/31/17

1. ABSTRACT/SUMMARY Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated. Treatment of PDCD remains a serious, unmet, challenge. There has never been a controlled trial of any intervention for PDCD; thus, there is no pro...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 08/09/16 - 07/31/17

? DESCRIPTION (provided by applicant): Adeno-associated virus (AAV) is a non-pathogenic human parvovirus, and recombinant AAV vectors have gained significant attention owing to their safety, and in some cases, clinical efficacy, in a number of Phase I/II clinical trials. However, relatively large vector doses are needed to achieve clinical eff...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 08/01/16 - 07/31/17

? DESCRIPTION (provided by applicant): The pursuit of novel therapies informed by the astounding advances in biomedical science of the past half century has been fruitful for many disorders. However, inherited muscle diseases such as muscular dystrophy remain stubbornly resistant to sophisticated molecular approaches to therapy. A few therapi...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 03/15/16 - 02/28/17

? DESCRIPTION (provided by applicant): Drug resistance to HIV is a major threat to achieving long-term viral suppression in HIV+ individuals. Up to 16% of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes, and incomplete viral suppression and virologic failure are often associated with ...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/30/15 - 09/29/16

DESCRIPTION (provided by applicant): Up to 30% of low birth weight preterm infants manifest some form of periventricular white matter injury (PWMI), making it the most common form of brain injury affecting premature infants. In the US, 150,000 infants per year are born at risk for PWMI, and about 25,000 children per year will develop PWMI. World...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/15/15 - 02/29/16

DESCRIPTION (provided by applicant): Dichloroacetate (DCA) has therapeutic potential in treating several rare and common life-threatening diseases of children and adults. These include congenital pyruvate dehydrogenase complex deficiency (PDCD), pulmonary arterial hypertension (PAH), diabetes, heart disease, cancer and other diseases in which it...